Intercept Pharmaceuticals (NASDAQ:ICPT) Rating Reiterated by Stifel Nicolaus

Stifel Nicolaus reiterated their hold rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report report published on Monday morning, AnalystRatings.com reports. Stifel Nicolaus currently has a $86.00 price objective on the biopharmaceutical company’s stock.

“We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis.”,” the firm’s analyst wrote.

Other equities analysts have also recently issued reports about the company. Oppenheimer lowered their price target on Intercept Pharmaceuticals from $170.00 to $160.00 and set an outperform rating on the stock in a report on Tuesday, August 6th. Cowen reissued a buy rating and set a $149.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, May 8th. Wedbush set a $243.00 price target on Intercept Pharmaceuticals and gave the company a buy rating in a report on Friday, July 5th. Cantor Fitzgerald lowered their price target on Intercept Pharmaceuticals from $191.00 to $186.00 and set an overweight rating on the stock in a report on Thursday, August 8th. Finally, BidaskClub raised Intercept Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, August 9th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $138.86.

Shares of ICPT opened at $64.64 on Monday. The business’s fifty day simple moving average is $69.81 and its two-hundred day simple moving average is $90.38. The company has a current ratio of 3.72, a quick ratio of 3.72 and a debt-to-equity ratio of 19.41. Intercept Pharmaceuticals has a 12 month low of $58.21 and a 12 month high of $133.74. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -5.95 and a beta of 1.32.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) EPS for the quarter, beating the consensus estimate of ($2.51) by $0.23. The business had revenue of $66.30 million for the quarter, compared to the consensus estimate of $58.78 million. Intercept Pharmaceuticals had a negative return on equity of 1,572.61% and a negative net margin of 143.57%. The company’s revenue was up 52.2% compared to the same quarter last year. During the same period last year, the business posted ($2.58) EPS. As a group, research analysts forecast that Intercept Pharmaceuticals will post -10.07 EPS for the current year.

In related news, insider Lisa Bright sold 595 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total value of $46,802.70. Following the transaction, the insider now directly owns 20,452 shares of the company’s stock, valued at approximately $1,608,754.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.00% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Intercept Pharmaceuticals by 14.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,337,622 shares of the biopharmaceutical company’s stock worth $186,005,000 after purchasing an additional 295,674 shares during the period. First Trust Advisors LP raised its holdings in Intercept Pharmaceuticals by 21.2% during the second quarter. First Trust Advisors LP now owns 1,093,108 shares of the biopharmaceutical company’s stock valued at $86,979,000 after acquiring an additional 191,132 shares during the period. Samsara BioCapital LLC raised its holdings in Intercept Pharmaceuticals by 56.8% during the second quarter. Samsara BioCapital LLC now owns 330,697 shares of the biopharmaceutical company’s stock valued at $26,314,000 after acquiring an additional 119,760 shares during the period. Northern Trust Corp raised its holdings in Intercept Pharmaceuticals by 8.6% during the second quarter. Northern Trust Corp now owns 293,776 shares of the biopharmaceutical company’s stock valued at $23,376,000 after acquiring an additional 23,309 shares during the period. Finally, Norges Bank bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at about $28,428,000. 77.24% of the stock is currently owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

See Also: Book Value Per Share in Stock Trading

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit